183 related articles for article (PubMed ID: 26879066)
1. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.
Marr K; Ronsley R; Nadel H; Douglas K; Gershony S; Strahlendorf C; Davis JH; Deyell RJ
Pediatr Blood Cancer; 2020 Apr; 67(4):e28167. PubMed ID: 31925920
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Arai S; Letsinger R; Wong RM; Johnston LJ; Laport GG; Lowsky R; Miklos DB; Shizuru JA; Weng WK; Lavori PW; Blume KG; Negrin RS; Horning SJ
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1145-54. PubMed ID: 20197102
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
8. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Castagna L; Magagnoli M; Balzarotti M; Sarina B; Siracusano L; Nozza A; Todisco E; Bramanti S; Mazza R; Russo F; Timofeeva I; Santoro A
Am J Hematol; 2007 Feb; 82(2):122-7. PubMed ID: 17019686
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Ding L; Wang HX; Xue M; Zhu L; Liu J; Yan HM; Duan LN; Wang ZD
Leuk Res; 2009 Sep; 33(9):e170-2. PubMed ID: 19403168
[No Abstract] [Full Text] [Related]
10. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
15. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi.
Levis M; Campbell BA; Matrone F; Grapulin L; Di Russo A; Buglione M; Iamundo De Cumis I; Simontacchi G; Ciammella P; Magli A; Pascale G; Meregalli S; MacManus M; Fanetti G; De Felice F; Furfaro G; Ciccone G; Ricardi U
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1008-1018. PubMed ID: 36822373
[TBL] [Abstract][Full Text] [Related]
16. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
Magagnoli M; Spina M; Balzarotti M; Timofeeva I; Isa L; Michieli M; Capizzuto R; Morenghi E; Castagna L; Tirelli U; Santoro A
Bone Marrow Transplant; 2007 Dec; 40(11):1019-25. PubMed ID: 17906705
[TBL] [Abstract][Full Text] [Related]
17. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Czyz A; Romejko-Jarosinska J; Knopinska-Posluszny W; Nowicki A; Lojko-Dankowska A; Gil L; Dytfeld D; Walewski J; Hellmann A; Komarnicki M
Leuk Lymphoma; 2013 May; 54(5):973-8. PubMed ID: 23025342
[TBL] [Abstract][Full Text] [Related]
19. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
20. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
